Product:
COLOFAST is a blood-based test kit for early colon cancer detection in blood.
Colofast is non-invasive and affordable.
Colofast is non-invasive and affordable.
Advantage:
COLOFAST detects cancer AND also precancerous lesions before they turn into
tumours (higher sensitivity for the detection of advanced adenomas than any
competitor including FIT, Epi procolon® and Cologuard®), increasing life
expectancy and reducing health cost in procedures and treatment.
Standard laboratory equipment and procedures required to use the kits.
tumours (higher sensitivity for the detection of advanced adenomas than any
competitor including FIT, Epi procolon® and Cologuard®), increasing life
expectancy and reducing health cost in procedures and treatment.
Standard laboratory equipment and procedures required to use the kits.
Market opportunity:
20B€ in USA and EU (200M people recommended for screening);
Pancreas and lung cancer kits in development
Pancreas and lung cancer kits in development
Amadix is a biotechnology company focused on early cancer detection in blood through
molecular diagnostics
molecular diagnostics
Commercial Status
Intellectual Property
WO granted, others pending
Tested in humans?
clinical validation done
FDA approval?
in process, expected for Q1 – 2021
CE approval?
in process, expected for Q2 – 2019
US reimbursement?
Not expected
EU reimbursement?
Not expected
Currently selling?
Exp. EU and US in 2019 as a service through the Lab Developed Test license
links of interest
